Cisplatin and oxaliplatin cytotoxic effects in sensitive and cisplatin-resistant human cervical tumor cells: Time and mode of application dependency

Anticancer Research

Volumn 29, Issue 10, 2009, Pages 3931-3937

  Martelli, Laura ^a   Ragazzi, Eugenio ^a   Di Mario, Francesco ^b   Basato, Marino ^a   Martelli, Mario ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

A431 and A431 Pt human cervical tumor cell lines; Cytotoxic effect; Platinum drugs; Prolonged drug incubation

Indexed keywords

CISPLATIN; CYCLOHEXANE DERIVATIVE; MISMATCH REPAIR PROTEIN; OXALIPLATIN;

AREA UNDER THE CURVE; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DOSE TIME EFFECT RELATION; DRUG EXPOSURE; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; ORGANOPLATINUM COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; UTERINE CERVICAL NEOPLASMS;

EID: 71949118332     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279, 2003.
2. Sanderson BJ, Ferguson LR and Denny WA: Mutagenic and carcinogenic properties of platinum-based anticancer drugs. Mutat Res 355: 59-70, 1996.
3. Perego P, Caserini C, Gatti L, Carenini N, Romanelli S, Supino R, Colangelo D, Viano I, Leone R, Spinelli S, Pezzoni G, Manzotti C, Farrell N and Zunino F: A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system. Mol Pharmacol 55:528-534, 1999. Erratum in: Mol Pharmacol 55: 1108, 1999.
4. Mann SC, Andrews PA and Howell SB: Short-term cis- diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol 25: 236-240, 1990.
5. Tobe ML and Burgess J: Inorganic Reaction Mechanisms. New York, Longman Limited, pp. 674, 1999.
6. Mishima M, Samimi G, Kondo A, Lin X and Howell SB: The cellular pharmacology of oxaliplatin resistance. Eur J Cancer 38: 1405-1412, 2002.
7. Woynarowski JM, Chapman WG, Napier C, Herzig MC and Juniewicz P: Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol 54: 770-777, 1998. (Pubitemid 28523169)
8. Martelli L, Di Mario F, Ragazzi E, Apostoli P, Leone R, Perego P and Fumagalli G: Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells. Biochem Pharmacol 72: 693-700, 2006. (Pubitemid 44233550)
9. Lanzi C, Perego P, Supino R, Romanelli S, Pensa T, Carenini N, Viano I, Colangelo D, Leone R, Apostoli P, Cassinelli G, Gambetta RA and Zunino F: Decreased drug accumulation and increased tolerance to DNA damage in tumor cells with a low level of cisplatin resistance. Biochem Pharmacol 55: 1247-1254, 1998. (Pubitemid 28206714)
10. Lindauer E and Holler E: Cellular distribution and cellular reactivity of platinum (II) complexes. Biochem. Pharmacol 52: 7-14, 1996. (Pubitemid 26199104)
11. Riccardi A, Ferlini C, Meco D, Mastrangelo R, Scambia G and Riccardi R: Antitumour activity of oxaliplatin in neuroblastoma cell lines. Eur J Cancer 35: 86-90, 1999. (Pubitemid 29079496)
12. Levasseur LM, Slocum HK, Rustum YM and Greco WR: Modeling of the time-dependency of in vitro drug cytotoxicity and resistance. Cancer Res 58: 5749-5761, 1998. (Pubitemid 29006416)
13. Hassan SB, Jonsson E, Larsson R and Karlsson MO: Model for time dependency of cytotoxic effect of CHS 828 in vitro suggests two different mechanisms of action. J Pharmacol Exp Ther 299: 1140-1147, 2001. (Pubitemid 33104987)
14. Cerè V, Grossi L, Munari D, Pollicino S, Martelli L and Martelli M: Platinum (II) complexes with stereochemically-defined thiepane dioxide diamine ligands as anticancer drugs. Anticancer Res 26: 1815-1819, 2006.
15. Martelli L, Di Mario F, Botti P, Ragazzi E, Martelli M and Kelland L: Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status. Biochem Pharmacol 74: 20-27, 2007. (Pubitemid 46802495)
16. Woynarowski JM, Faivre S, Herzig MC, Arnett B, Chapman WG, Trevino AV, Raymond E, Chaney SG, Vaisman A, Varchenko M and Juniewicz PE: Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 58: 920-927, 2000.
17. Luo FR, Wyrick SD and Chaney SG: Biotransformations of oxaliplatin in rat blood in vitro. J Biochem Mol Toxicol 13: 159-169, 1999.
18. Luo FR, Yen TY, Wyrick SD and Chaney SG: High-performance liquid chromatographic separation of the biotransformation products of oxaliplatin. J Chromatogr B Biomed Sci Appl 724: 345-356, 1999. (Pubitemid 29148096)
19. Luo FR, Wyrick SD and Chaney SG: Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells. Oncol Res 10: 595-603, 1998.
20. Ghezzi A, Aceto M, Cassino C, Gabano E and Osella D: Uptake of antitumor platinum (II)-complexes by cancer cells, assayed by inductively coupled plasma mass spectrometry (ICP-MS). J Inorg Biochem 98: 73-78, 2004. (Pubitemid 37495012)
21. Reile H, Bernhardt G, Koch M, Schönenberger H, Hollstein M and Lux F: Chemosensitivity of human MCF-7 breast cancer cells to diastereoisomeric diaqua(1,2-diphenylethylenediamine) platinum (II) sulfates and specific platinum accumulation. Cancer Chemother Pharmacol 30: 113-122, 1992.
22. Tacka KA, Szalda D, Souid AK, Goodisman J and Dabrowiak JC: Experimental and theoretical studies on the pharmacodynamics of cisplatin in Jurkat cells. Chem Res Toxicol 17: 1434-1444, 2004. (Pubitemid 39532312)
23. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehmé A, Christen RD and Howell SB: The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56: 4881-4886, 1996. (Pubitemid 26374423)
24. Chaney SG and Vaisman A: Specificity of platinum-DNA adduct repair. J Inorg Biochem 77: 71-81, 1999.
25. Zdraveski ZZ, Mello JA, Farinelli CK, Essigmann JM and Marinus MG: MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA. J Biol Chem 277: 1255-1260, 2002.
26. Chaney SG, Campbell SL, Bassett E, Wu Y: Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol 53: 3-11, 2005. (Pubitemid 39656106)